U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07383506) titled 'A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors' on Jan. 26.
Brief Summary: This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
PIK3CA Mutations
Advanced Solid Tumors, Adult
Endometrial Cancer
HR Positive/HER-2 Negative Breast Cancer
HER2-low Breast Cancer
Intervention: ...